-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, listed companies in the pharmaceutical industry are releasing their 2021 annual performance reports one after another.
At the same time, many companies have disclosed their research and development expenses for 2021 in their reports
.
According to the author's incomplete statistics, at least 3 pharmaceutical companies have released data on R&D expenses in 2021, including Zejing Pharmaceuticals, Huiyu Pharmaceuticals and Legend Bio.
On the whole, the R&D expenses of the three companies in 2021 will show an upward trend
.
Zejing Pharmaceuticals The 2021 performance report disclosed by Zejing Pharmaceuticals shows that the company has a net loss of 414 million yuan in 2021
.
However, during the reporting period, the company's research and development projects continued to advance, and research and development expenditures further increased.
The research and development expenses in 2021 were 502 million yuan, an increase of 188 million yuan over the previous year, and a year-on-year increase of 59.
75%
.
It is understood that Zejing Pharmaceutical mainly focuses on the R&D and production of innovation-driven new drugs in multiple therapeutic areas such as oncology, hemorrhagic and blood diseases, hepatobiliary diseases and immune-inflammatory diseases
.
The company has three R&D centers, located in Kunshan, Jiangsu, Zhangjiang, Shanghai, and California, USA
.
At present, with years of precipitation and accumulation in the field of new drug research and development, two characteristic core technology platforms have been successfully established, namely the precision small molecule drug research and development and industrialization platform and the complex recombinant protein new drug research and development and industrialization platform
.
As of the end of 2021, the company is developing 42 R&D projects for 16 new drugs, and the product line of its subsidiary GENSUN includes more than 10 new candidate antibody drugs
.
Huiyu Pharmaceutical's 2021 performance report shows that the company will invest 247 million yuan in research and development in 2021, an increase of 178.
51% over the previous year, mainly due to the substantial increase in investment in innovative drug research and development and API research and development
.
In order to maintain the advantages of research and development and technology, the research and development expenses of Huiyu Pharmaceutical have been increasing in the past three years.
From 2018 to 2020, the research and development expenses of Huiyu Pharmaceutical were 39.
1498 million yuan, 55.
6155 million yuan and 88.
7739 million yuan respectively
.
At present, Huiyu Pharmaceutical has more than 450 R&D personnel, accounting for more than 40% of the total number of the company
.
Among them, the number of innovative drug teams has exceeded 100
.
Based on the advantages in R&D and talents, Huiyu Pharmaceutical has achieved a number of achievements in the field of pharmaceuticals in recent years
.
Up to now, Huiyu Pharmaceutical has 7 drugs approved for marketing in China, including Pemetrexed Disodium for Injection, Docetaxel Injection, Azacitidine for Injection, and Paclitaxel Injection
.
Legend Bio On February 18, GenScript disclosed the 2021 results of Legend Bio, a listed subsidiary, with an estimated loss of approximately $365.
3 million to $397.
4 million for the full year, and an adjusted loss of approximately $335.
8 million to $364.
7 million
.
Of this, R&D expenses were approximately $297.
9 million to $321.
8 million, primarily due to continued investment in its lead product candidate ciltacabtagene autoleucel (cilta-cel) and other product candidates in Legend Bio's pipeline
.
According to the data, ciltacabtagene autoleucel (cilta-cel) is a gene-edited autologous CAR-T cell therapy jointly developed by Legend Bio and Janssen for the treatment of adults with relapsed or refractory multiple myeloma (RRMM).
.
Previously, the FDA has granted cilta-cel breakthrough therapy and orphan drug designation, and the European Medicines Agency has also granted the product orphan and priority medicine (PRIME) designation and accelerated review
.
It is worth mentioning that this product is the first self-developed cell therapy in China that has been approved by the FDA for clinical trials, and it is also the first breakthrough treatment product in China
.
The FDA originally planned to approve cilta-cel on November 29, 2021, but the FDA decided to extend it to February 28, 2022, due to a request to review additional information on "updated analytical methods
.
" The industry expects that if the product is successfully approved, it will become the second BCMA-targeting CAR-T cell therapy marketed in the United States
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
At the same time, many companies have disclosed their research and development expenses for 2021 in their reports
.
According to the author's incomplete statistics, at least 3 pharmaceutical companies have released data on R&D expenses in 2021, including Zejing Pharmaceuticals, Huiyu Pharmaceuticals and Legend Bio.
On the whole, the R&D expenses of the three companies in 2021 will show an upward trend
.
Zejing Pharmaceuticals The 2021 performance report disclosed by Zejing Pharmaceuticals shows that the company has a net loss of 414 million yuan in 2021
.
However, during the reporting period, the company's research and development projects continued to advance, and research and development expenditures further increased.
The research and development expenses in 2021 were 502 million yuan, an increase of 188 million yuan over the previous year, and a year-on-year increase of 59.
75%
.
It is understood that Zejing Pharmaceutical mainly focuses on the R&D and production of innovation-driven new drugs in multiple therapeutic areas such as oncology, hemorrhagic and blood diseases, hepatobiliary diseases and immune-inflammatory diseases
.
The company has three R&D centers, located in Kunshan, Jiangsu, Zhangjiang, Shanghai, and California, USA
.
At present, with years of precipitation and accumulation in the field of new drug research and development, two characteristic core technology platforms have been successfully established, namely the precision small molecule drug research and development and industrialization platform and the complex recombinant protein new drug research and development and industrialization platform
.
As of the end of 2021, the company is developing 42 R&D projects for 16 new drugs, and the product line of its subsidiary GENSUN includes more than 10 new candidate antibody drugs
.
Huiyu Pharmaceutical's 2021 performance report shows that the company will invest 247 million yuan in research and development in 2021, an increase of 178.
51% over the previous year, mainly due to the substantial increase in investment in innovative drug research and development and API research and development
.
In order to maintain the advantages of research and development and technology, the research and development expenses of Huiyu Pharmaceutical have been increasing in the past three years.
From 2018 to 2020, the research and development expenses of Huiyu Pharmaceutical were 39.
1498 million yuan, 55.
6155 million yuan and 88.
7739 million yuan respectively
.
At present, Huiyu Pharmaceutical has more than 450 R&D personnel, accounting for more than 40% of the total number of the company
.
Among them, the number of innovative drug teams has exceeded 100
.
Based on the advantages in R&D and talents, Huiyu Pharmaceutical has achieved a number of achievements in the field of pharmaceuticals in recent years
.
Up to now, Huiyu Pharmaceutical has 7 drugs approved for marketing in China, including Pemetrexed Disodium for Injection, Docetaxel Injection, Azacitidine for Injection, and Paclitaxel Injection
.
Legend Bio On February 18, GenScript disclosed the 2021 results of Legend Bio, a listed subsidiary, with an estimated loss of approximately $365.
3 million to $397.
4 million for the full year, and an adjusted loss of approximately $335.
8 million to $364.
7 million
.
Of this, R&D expenses were approximately $297.
9 million to $321.
8 million, primarily due to continued investment in its lead product candidate ciltacabtagene autoleucel (cilta-cel) and other product candidates in Legend Bio's pipeline
.
According to the data, ciltacabtagene autoleucel (cilta-cel) is a gene-edited autologous CAR-T cell therapy jointly developed by Legend Bio and Janssen for the treatment of adults with relapsed or refractory multiple myeloma (RRMM).
.
Previously, the FDA has granted cilta-cel breakthrough therapy and orphan drug designation, and the European Medicines Agency has also granted the product orphan and priority medicine (PRIME) designation and accelerated review
.
It is worth mentioning that this product is the first self-developed cell therapy in China that has been approved by the FDA for clinical trials, and it is also the first breakthrough treatment product in China
.
The FDA originally planned to approve cilta-cel on November 29, 2021, but the FDA decided to extend it to February 28, 2022, due to a request to review additional information on "updated analytical methods
.
" The industry expects that if the product is successfully approved, it will become the second BCMA-targeting CAR-T cell therapy marketed in the United States
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
